USING YOUR DATA AND A DECISION ANALYSIS MODEL TO EVALUATE COST-EFFECTIVENESS OF PREOPERATIVE MORBIDITY REDUCING STRATEGIES FOR VASCULAR SURGERY PATIENTS

1995 ◽  
Vol 80 (Supplement) ◽  
pp. SCA64
Author(s):  
S. Mantha ◽  
J. F. Foss ◽  
J. E. Ellis ◽  
L. A. Fleisher ◽  
M. F. Roizen
Keyword(s):  
Cost Effectiveness ◽  
Vascular Surgery ◽  
Decision Analysis ◽  
Decision Analysis Model ◽  
Analysis Model

Percutaneous Stenting of Incidental Unilateral Renal Artery Stenosis: Decision Analysis of Costs and Benefits

2003 ◽  
Vol 10 (3) ◽  
pp. 546-556 ◽  
Author(s):  
David A. Axelrod ◽  
A. Mark Fendrick ◽  
Ruth C. Carlos ◽  
Robert J. Lederman ◽  
James B. Froehlich ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Decision Analysis ◽  
Renal Artery ◽  
Incremental Cost ◽  
Renal Artery Stenosis ◽  
Cost Effective ◽  
Artery Stenosis ◽  
Decision Analysis Model ◽  
Analysis Model ◽  
Refractory Hypertension

Purpose: To determine the incremental cost-effectiveness of prophylactic percutaneous transluminal angioplasty with stent placement (PTA-S) in patients with incidentally discovered, asymptomatic renal artery stenosis (RAS) compared to delaying PTA-S until patients develop refractory hypertension or renal insufficiency (therapeutic PTA-S). Methods: The Markov decision analysis model was used to determine the incremental cost per quality adjusted life year (QALY) saved for prophylactic PTA-S as compared to therapeutic PTA-S in a hypothetical cohort of patients with 50% unilateral atherosclerotic RAS followed from age 61 to death. Results: Prophylactic PTA-S compared to therapeutic PTA-S results in more QALYs/patient (10.9 versus 10.3) at higher lifetime costs ($23,664 versus $16,558). The incremental cost effectiveness of prophylactic PTA-S was estimated to be $12,466/QALY. Prophylactic stenting was not cost effective (>$50,000/QALY) if the modeled incidence of stent restenosis exceeded 15%/year and the incidence of progression in the contralateral renal artery was <2% of arteries/year. Conclusions: PTA-S of incidental, asymptomatic unilateral RAS may improve patients' quality of life at an acceptable incremental cost. However, this technology should be used hesitantly until a randomized comparison confirms its effectiveness.

scholarly journals The cost-effectiveness of palivizumab in infants with cystic fibrosis in the Canadian setting: A decision analysis model

2016 ◽  
Vol 13 (3) ◽  
pp. 599-606 ◽  
Author(s):  
Ashleigh A. McGirr ◽  
Kevin L. Schwartz ◽  
Upton Allen ◽  
Melinda Solomon ◽  
Beate Sander
Keyword(s):  
Cystic Fibrosis ◽  
Cost Effectiveness ◽  
Decision Analysis ◽  
Decision Analysis Model ◽  
Analysis Model ◽  
Canadian Setting ◽  
The Cost

A Cost-Effectiveness Clinical Decision Analysis Model for Treatment of Schizophrenia

2002 ◽  
Vol 33 (6) ◽  
pp. 572-580 ◽  
Author(s):  
Cynthia S Palmer ◽  
Elizabeth Brunner ◽  
Luis Guillermo Ruı́z-Flores ◽  
Francisco Paez-Agraz ◽  
Dennis A Revicki
Keyword(s):  
Cost Effectiveness ◽  
Decision Analysis ◽  
Clinical Decision ◽  
Decision Analysis Model ◽  
Analysis Model
Sign in / Sign up

Export Citation Format

Share Document